S'abonner

Prophylactic application of dexmedetomidine reduces the incidence of emergence delirium in children: A systematic review and meta-analysis - 08/11/24

Doi : 10.1016/j.accpm.2024.101426 
Sai-hao Fu a, 1, Meng-rong Miao a, 1, Lu-yao Zhang a, Jing Bian a, Yun-xiang Fu b, Jia-qiang Zhang c, , Ming-yang Sun c,
a Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou 450003, China 
b Department of Anesthesiology and Perioperative Medicine, People's Hospital of Henan University, Henan Provincial People's Hospital, Zhengzhou 450003, China 
c Department of Anesthesiology and Perioperative Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou 450003, Henan Province, China 

Corresponding authors.

Abstract

Background

Emergence delirium (ED) is a common postoperative cognitive dysfunction in children. ED may cause distress to patients and their families in the early post-anesthesia period and have long-term adverse effects on children.

The primary purpose

was to verify whether dexmedetomidine can reduce the occurrence of ED in children.

Research type

Systematic review and meta-analysis of RCTs.

Data acquisition

A search was conducted on Web of Science, WHO Trials, Cochrane Library, Clinical Trials.gov, and PubMed for all published studies from inception to 23 Oct. 2022.

Eligibility criteria

Randomized clinical trials that met the following criteria: patients aged 1–18 years, study site in the PACU (Post-anesthesia care unit), incidence of ED as the primary outcome, and prophylactic use of dexmedetomidine defined as injected before admission to the PACU.

Results

A total of 7 randomized trials were included (6 studies during eye and neck surgery, 1 during hernia surgery), involving 512 patients (257 (50.1%) with dexmedetomidine, and 250 (49.9%) with control. ED was observed in 17.51% of the patients treated with dexmedetomidine and in 43.14% of those receiving control (risk ratio (RR) = 0.40, 95 % confidence interval [CI] [0.30−0.55], P < 0.00001). Additionally, the prophylactic application of dexmedetomidine also reduced the occurrence of Post-Operating Nausea and Vomiting (RR = 0.24, 95%CI [0.12−0.49], P = 0.0001) and PACU stay time after extubation (mean difference (MD) = −1.57, 95%CI [−3.07 to −0.07], P = 0.04). However, sensitivity analysis of RCTs showed that our effect estimates were not stable (MD = −1.78, 95%CI [−4.18−0.62], P = 0.15).

Conclusion

The prophylactic use of dexmedetomidine was associated with a reduction of ED. However, our findings only apply to eye and neck surgery.

Trial registration

PROSPERO: CRD42022371840.

Le texte complet de cet article est disponible en PDF.

Highlights

Question: What is the effect of dexmedetomidine on emergence delirium in children undergoing eye and neck surgery?
Findings: This meta-analysis, which enrolled 512 patients, found a lower incidence of emergence delirium among patients who received dexmedetomidine than among patients in the control group (17.51% vs. 43.14%, respectively).
Meaning: The findings of this meta-analysis suggest that dexmedetomidine may be a reliable strategy for improving emergence delirium in children.

Le texte complet de cet article est disponible en PDF.

Plan


© 2024  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 43 - N° 6

Article 101426- décembre 2024 Retour au numéro
Article précédent Article précédent
  • Hypocalcemia in critical care settings, from its clinical relevance to its treatment: A narrative review
  • Catarina Fernandes, Luciano Pereira
| Article suivant Article suivant
  • Intraoperative ketamine and pain after video-assisted thoracoscopic surgery (VATS): A systematic review and meta-analysis
  • Umar Akram, Zain Ali Nadeem, Haider Ashfaq, Eeshal Fatima, Hamza Ashraf, Muhammad Ahmed Raza, Shahzaib Ahmed, Arsalan Nadeem, Sana Rehman, Muhammad Hassan Ahmad

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.